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1. INTRODUCTION {#ijlh13273-sec-0005}
===============

Since early December 2019, pneumonia cases with unknown cause emerged in Wuhan[^1^](#ijlh13273-bib-0001){ref-type="ref"}; then, the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) was identified as the causative agent of this mysterious pneumonia.[^2^](#ijlh13273-bib-0002){ref-type="ref"} At the time of writing this paper, a total number of more than two million confirmed cases with coronavirus disease 2019 (COVID‐19) have been identified, spanning 181 countries and regions of the whole world.

Patients infected by SARS‐CoV‐2 are generally classified as mild, severe, and critical types in accordance with the severity of clinical symptoms.[^3^](#ijlh13273-bib-0003){ref-type="ref"} According to previous study,[^1^](#ijlh13273-bib-0001){ref-type="ref"}, [^4^](#ijlh13273-bib-0004){ref-type="ref"}, [^5^](#ijlh13273-bib-0005){ref-type="ref"}, [^6^](#ijlh13273-bib-0006){ref-type="ref"} the severe or critical patients with COVID‐19 markedly appear to have clinical manifestations of coagulation dysfunction. However, the correlations between coagulation and clinical outcomes, and the factors leading to coagulation dysfunction of COVID‐19 patients were not fully elaborated. In this study, the complete coagulation parameters of severe COVID‐19 patients and its influence on clinical outcomes were shown and analyzed, which may be helpful for formulating appropriate therapeutic strategy on coagulopathy of COVID‐19.

2. MATERIALS AND METHODS {#ijlh13273-sec-0006}
========================

2.1. Patients {#ijlh13273-sec-0007}
-------------

All consecutive severe patients (N = 71) with confirmed SARS‐CoV‐2 infection who had been tested by real‐time RT‐PCR for viral infection and had conducted a test of coagulation function within 3 days on admission and were treated in Wuhan First Hospital from February 12 to March 20, 2020, were enrolled. The study was approved by the Hospital Ethics Committee, and oral informed consent was obtained from each of the patients. The patients enrolled in this study were treated according to WHO interim guidance,[^7^](#ijlh13273-bib-0007){ref-type="ref"} and patients\' conditions and clinical outcomes were determined by reference to the notice on the issuance of strategic guidelines for diagnosis and treatment of COVID‐19.[^8^](#ijlh13273-bib-0008){ref-type="ref"} A patient was categorized as severe case if any of the bellowed clinical scenes appeared: (a) respiratory rate ≥30/min; (a) oxygen saturation ≤93%; and (c) arterial partial pressure of oxygen (PaO~2~)/ fraction of inspired oxygen (FiO~2~) ≤300 mmHg (1 mmHg = 0.133 kPa). A patient was categorized as critically ill case if any of the bellowed clinical scenes appeared: (a) with acute respiratory distress syndrome (ARDS) and needing mechanical ventilation either invasively or noninvasively; (b) shock; and (c) complication of organ functional failure and need intensive care unit support. All enrolled patients were severe cases with COVID‐19 on admission and then were divided into two groups, the aggravated group and the nonaggravated group, respectively, basing on whether the patients\' conditions turned to critically ill or not after admission.

2.2. Data collection {#ijlh13273-sec-0008}
--------------------

The general information (age, sex, initial symptoms, coexisting disorders), clinical, laboratory, and radiological characteristics data of the enrolled patients on admission were extracted from electronic medical records. For coagulation data, the first results of patients within 3 days on admission were shown and analyzed. The measurement process of coagulation function was conducted with Sysmex CS5100 Automatic Blood Coagulation Analyzer (Sysmex) using corollary reagents (Siemens). The coagulation function was assessed by the parameters of fibrinogen (FIB, normal range 2‐4 g/L), activated partial thromboplastin time (APTT, normal range 20‐40 seconds), prothrombin time (PT, normal range 9‐13 seconds), thrombin time (TT, normal range 14‐21 seconds), international normalized ratio (INR, normal range 0.7‐1.3), D‐Dimers (D‐D, normal range 0‐0.55 mg/L), fibrin/FIB degradation products (FDP, normal range 0‐5 mg/L), and antithrombin (AT, normal range 75%‐141%). FIB, APTT, PT, and TT were tested using the clot‐based method. D‐D and FDP were tested using the method of immunoturbidimetry method. AT was tested using the method of chromogenic substrate. For other laboratory data (liver function test, lactate dehydrogenase \[LDH, normal range 114‐250 U/L\], and C‐reactive protein \[CRP, normal range 0‐5 mg/L\]), the relevant results were tested using Beckman Coulter Chemistry Analyzer AU5800 (Beckman) and corollary reagents (Beckman), and were recorded and analyzed based on the test time closest to coagulation test. The liver function was assessed by the parameters of alanine aminotransferase (ALT, normal range 7‐45 U/L), aspartate aminotransferase (AST, normal range 13‐35 U/L), total bilirubin (TBiL, normal range 2‐24 μmol/L), and direct bilirubin (DBiL, normal range 0‐7 μmol/L). In addition, the coagulation test results obtained from 61 healthy controls who had conducted physical examinations in Wuhan First Hospital in February 2019 were used as a reference.

2.3. Statistical analysis {#ijlh13273-sec-0009}
-------------------------

Continuous variables were described as the means and standard deviations or medians and interquartile ranges (IQR) values. Categorical variables were expressed as the counts and percentages. Independent group*t* tests were applied to continuous variables that were normally distributed; otherwise, the Mann‐Whitney test was used. Categorical variables were compared using the Chi‐square tests, while the Fisher exact test was used when the data were limited. Statistical analyses were performed using Statistical Package for the Social Sciences (SPSS) version 22.0 software. A two‐sided α of less than 0.05 was considered statistically significant.

3. RESULTS {#ijlh13273-sec-0010}
==========

3.1. Demographics and patient characteristics {#ijlh13273-sec-0011}
---------------------------------------------

The clinical characteristics of the 71 patients with COVID‐19 enrolled in this study are shown in Table [1](#ijlh13273-tbl-0001){ref-type="table"}. The median age was 65.0 years (IQR, 56.5‐71.5), and 38 (53.5%) of the patients were men. The median time from illness onset to hospital admission of these patients was 12.0 days (IQR, 7.0‐21.0). On admission, most (97.2%) of the patients possessed a typical CT finding of ground‐glass opacity and/or patchy shadowing. Of these patients, the most common initial symptoms were fever (48 \[67.6%\]), dry cough (33 \[46.5%\]), and chest tightness (78 \[32.8%\]). Hypertension (22 \[31.0%\]), diabetes (15 \[21.1%\]), and cardiovascular disease (11 \[15.5%\]) were the most common coexisting disorders. According to whether the patients\' conditions worsened further or not after admission, the enrolled patients were divided into two groups: the aggravated group and the nonaggravated group, respectively (Table [1](#ijlh13273-tbl-0001){ref-type="table"}). Between the two group patients, no statistical differences were found in baseline characteristics except for initial symptoms of dry cough (*P* \< .05). In addition, patients in the aggravated group evidently had a longer hospital stay (34.0 days \[IQR, 31.5‐35.0\] vs 23.0 days \[IQR, 18.8‐31.0\]; *P* \< .001) and a higher mortality (23.5% vs 0.0%; *P* \< .001) compared with patients in the nonaggravated group.

###### 

Demographic and baseline characteristics of 71 enrolled COVID‐19 patients

  Characteristics                                               All patients (N = 71)   Aggravated (N = 17)   Nonaggravated (N = 54)   *P* value
  ------------------------------------------------------------- ----------------------- --------------------- ------------------------ -----------
  Age, Median (IQR) -- year                                     65.0 (56.5‐71.5)        68.0 (62.0‐72.0)      65.0 (56.0‐71.0)         .169
  Sex                                                                                                                                  
  Male                                                          38 (53.5)               10 (58.8)             28 (51.9)                .615
  Female                                                        33 (46.5)               7 (41.2)              26 (48.1)                
  Onset of symptom to hospital admission -- day                 12.0 (7.0‐21.0)         12.0 (10.0‐17.5)      11.5 (7.0‐21.0)          .622
  CT findings of ground‐glass opacity and/or patchy shadowing   69 (97.2)               17 (100)              52 (96.3)                \>.99
  Initial symptoms                                                                                                                     
  Fever                                                         48 (67.6)               13 (76.5)             35 (64.8)                .370
  Dry cough                                                     33 (46.5)               4 (23.5)              29 (53.7)                .030
  Chest tightness                                               15 (21.1)               3 (17.6)              12 (22.2)                .950
  Fatigue                                                       13 (18.3)               3 (17.6)              10 (18.5)                \>.99
  Chest pain                                                    4 (5.6)                 1 (5.9)               3 (5.6)                  \>.99
  Shortness of breath                                           3 (4.2)                 0 (0.0)               3 (5.6)                  \>.99
  Dyspnea                                                       2 (2.8)                 0 (0.0)               2 (3.7)                  \>.99
  Vomiting                                                      2 (2.8)                 1 (5.9)               1 (1.9)                  .424
  Chill                                                         1 (1.4)                 0 (0.0)               1 (1.9)                  \>.99
  Diarrhea                                                      1 (1.4)                 0 (0.0)               1 (1.9)                  \>.99
  Headache                                                      1 (1.4)                 1 (5.9)               0 (0.0)                  .239
  Nausea                                                        1 (1.4)                 0 (0.0)               1 (1.9)                  \>.99
  Dizziness                                                     1 (1.4)                 0 (0.0)               1 (1.9)                  \>.99
  Anorexia                                                      1 (1.4)                 0 (0.0)               1 (1.9)                  \>.99
  Coexisting disorders                                                                                                                 
  Hypertension                                                  22 (31.0)               6 (35.3)              16 (29.6)                .660
  Diabetes                                                      15 (21.1)               3 (17.6)              12 (22.2)                .950
  Cardiovascular disease                                        11 (15.5)               3 (17.6)              8 (14.8)                 \>.99
  Chronic respiratory disease                                   4 (5.6)                 1 (5.9)               3 (5.6)                  \>.99
  Hepatopathy                                                   4 (5.6)                 2 (11.8)              2 (3.7)                  .241
  Cerebrovascular disease                                       1 (1.4)                 1 (5.9)               0 (0.0)                  .239
  Malignancy                                                    1 (1.4)                 0 (0.0)               1 (1.9)                  \>.99
  Clinical outcomes                                                                                                                    
  Length of hospital stay -- day                                27.0 (19.0‐33.0)        34.0 (31.5‐35.0)      23.0 (18.8‐31.0)         \<.001
  Mortality                                                     4 (5.6)                 4 (23.5)              0 (0.0)                  \<.001

Data are median (IQR) or n (%). *P* values comparing patients in the aggravated group and in the nonaggravated group are from Chi‐square test, Fisher\'s exact test, or Mann‐Whitney *U* test.

Aggravated, patients in the aggravated group; Nonaggravated, patients in the nonaggravated group.
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3.2. Comparison of blood coagulation between COVID‐19 patients and healthy controls {#ijlh13273-sec-0012}
-----------------------------------------------------------------------------------

The differences of hemostasis function between COVID‐19 patients and healthy controls were shown on account of the assessment of eight parameters (Table [2](#ijlh13273-tbl-0002){ref-type="table"}). The FIB value of COVID‐19 patients was higher than that of healthy controls (3.96 g/L \[IQR, 3.42‐4.17\] vs 2.89 g/L \[IQR, 2.50‐3.26\]; *P* \< .001), which indicates blood of COVID‐19 patients is in hypercoagulable state in comparison with healthy individuals. However, the values of APTT (26.30 seconds \[IQR, 24.10‐28.90\] vs 24.10 seconds \[IQR, 21.75‐26.15\]; *P* \< .001), PT (11.60 seconds \[IQR, 11.00‐12.10\] vs 11.00 seconds \[IQR, 10.65‐11.50\]; *P* \< .001), and INR (1.03 \[IQR, 0.97‐1.08\] vs 0.97 \[IQR, 0.94‐1.02\]; *P* \< .001) were simultaneously found to be higher in COVID‐19 patients compared with healthy controls. Importantly, the FDP (3.20 mg/L \[IQR, 1.90‐8.00\] vs 0.90 mg/L \[IQR, 0.55‐1.10\]; *P* \< .001) and D‐D (0.55 mg/L \[IQR, 0.30‐3.24\] vs 0.29 mg/L \[IQR, 0.18‐0.46\]; *P* \< .001) values were both higher in COVID‐19 patients than those in controls, whereas the AT value was lower in COVID‐19 patients than that in controls (84.0% \[IQR, 76.50‐90.20\] vs 86.9% \[IQR, 80.45‐92.70\]; *P* \< .05). Nevertheless, no difference could be observed in the TT value between the two group patients (*P* \> .05). Taken the data above all, significant differences can be concurrently found in parameters representing the functions of coagulation, fibrinolysis, and anticoagulation between COVID‐19 patients and healthy individuals.

###### 

Comparison of coagulation function between COVID‐19 patients and healthy controls

  Parameters   Patients (N = 71)     Controls (N = 61)     *P* value
  ------------ --------------------- --------------------- -----------
  FIB, g/L     3.96 (3.42‐4.17)      2.89 (2.50‐3.26)      \<.001
  APTT, s      26.30 (24.10‐28.90)   24.10 (21.75‐26.15)   \<.001
  PT, s        11.60 (11.00‐12.10)   11.00 (10.65‐11.50)   \<.001
  TT, s        18.00 (17.10‐19.00)   18.00 (17.20‐18.45)   .340
  INR          1.03 (0.97‐1.08)      0.97 (0.94‐1.02)      \<.001
  FDP, mg/L    3.20 (1.90‐8.00)      0.90 (0.55‐1.10)      \<.001
  D‐D, mg/L    0.55 (0.30‐3.24)      0.29 (0.18‐0.46)      \<.001
  AT, %        83.00 (76.50‐90.20)   86.90 (80.45‐92.70)   .032

Data are median (IQR). *P* values comparing the COVID‐19 patients and the healthy controls are from Mann‐Whitney *U* test. Patients = patients with COVID‐19.

Abbreviations: APTT, activated partial thromboplastin time; AT, antithrombin; Controls, healthy controls; D‐D, D‐Dimers; FDP, fibrin/fibrinogen degradation products; FIB, fibrinogen; INR, international normalized ratio; PT, prothrombin time; TT, thrombin time.
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3.3. Comparison of laboratory findings on admission and clinical outcomes between the aggravated and nonaggravated patients {#ijlh13273-sec-0013}
---------------------------------------------------------------------------------------------------------------------------

To make clear the relationship between blood coagulation on admission and clinical outcomes of severe COVID‐19 patients, several hematological findings in laboratory were shown and compared between the aggravated and nonaggravated patients (Table [3](#ijlh13273-tbl-0003){ref-type="table"}). For coagulation function test, the values of APTT (30.40 seconds \[IQR, 24.30‐34.65\] vs 26.10 seconds \[IQR, 24.10‐28.43\]; *P* \< .05), PT (12.00 seconds \[IQR, 11.75‐12.80\] vs 11.50 seconds \[IQR, 10.90‐11.83\]; *P* \< .001), and INR (1.07 \[IQR, 1.05‐1.14\] vs 1.02 \[IQR, 0.96‐1.05\]; *P* \< .001) were simultaneously found to be higher in the aggravated patients compared with patients in the nonaggravated group. However, no statistical differences were found in the percentage values of APTT, PT, and INR above their normal ranges between two group patients (*P* \> .05). The FDP (13.00 mg/L \[IQR, 5.50‐65.05\] vs 2.40 mg/L \[IQR, 1.70‐5.00\]; *P* \< .001) and D‐D (5.95 mg/L \[IQR, 1.23‐20.08\] vs 0.44 mg/L \[IQR, 0.25‐1.19\]; *P* \< .001) values were both higher in the aggravated patients than those in the nonaggravated patients, whereas the AT value was lower in the aggravated patients than that in the nonaggravated patients (76.10% \[IQR, 63.40‐81.35\] vs 84.25% \[IQR, 79.48‐91.95\]; *P* \< .001). In addition, significant differences could be found in the percentage values of FDP and D‐D above their normal ranges (*P* \< .001) and AT below the normal range between two group patients (*P* \< .01). Notably, the values of FIB and TT did not differ in these two group patients (*P* \> .05).

###### 

Laboratory findings on admission and clinical outcomes of COVID‐19 patients

  Parameters                             Aggravated (N = 17)      Nonaggravated (N = 54)   *P* value
  -------------------------------------- ------------------------ ------------------------ -----------
  Coagulation function test                                                                
  FIB (g/L; normal range 2.00‐4.00)      3.84 (3.51‐4.40)         3.96 (3.42‐4.17)         .532
  Increased                              8 (47.1)                 19 (35.2)                .379
  APTT (s; normal range 20.00‐40.00)     30.40 (24.30‐34.65)      26.10 (24.10‐28.43)      .027
  Increased                              0 (0.0)                  0 (0.0)                  \>.99
  PT (s; normal range 9.00‐13.00)        12.00 (11.75‐12.80)      11.50 (10.90‐11.83)      \<.001
  Increased                              3 (17.6)                 3 (5.6)                  .144
  TT (s; normal range 14.00‐21.00)       17.20 (16.95‐19.35)      18.10 (17.30‐19.00)      .200
  INR (normal range 0.70‐1.30)           1.07 (1.05‐1.14)         1.02 (0.96‐1.05)         \<.001
  Increased                              1 (5.9)                  0 (0.0)                  .239
  FDP (mg/L; normal range 0.0‐5.0)       13.00 (5.50‐65.05)       2.40 (1.70‐5.00)         \<.001
  Increased                              14 (82.4)                13 (24.1)                \<.001
  D‐D (mg/L; normal range 0.00‐0.55)     5.95 (1.23‐20.08)        0.44 (0.25‐1.19)         \<.001
  Increased                              15 (88.2)                18 (33.3)                \<.001
  AT (%; normal range 75.0‐141.0)        76.10 (63.40‐81.35)      84.25 (79.48‐91.95)      \<.001
  Decreased                              7 (41.2)                 5 (9.3)                  .007
  Liver function test                                                                      
  ALT (U/L; normal range 7‐45)           25.00 (15.50‐112.00)     24.50 (13.75‐40.00)      .217
  Increased                              7 (41.1)                 12 (22.2)                .220
  AST (U/L; normal range 13‐35)          38.00 (24.50‐88.50)      23.00 (17.75‐35.00)      .003
  Increased                              9 (52.9)                 12 (22.2)                .016
  TBiL (μmol/L; normal range 2.0‐24.0)   14.30 (11.45‐18.55)      11.30 (8.58‐15.03)       .036
  Increased                              2 (11.8)                 3 (5.6)                  .587
  DBiL (μmol/L; normal range 0.0‐7.0)    2.80 (1.30‐4.45)         1.50 (1.08‐2.35)         .026
  Increased                              1 (5.9)                  1 (1.9)                  .424
  Diagnostic enzyme index                                                                  
  LDH (U/L; normal range 114‐250)        382.00 (271.00‐515.00)   180.00 (157.00‐218.00)   \<.001
  Increased                              14 (82.4)                6 (11.1)                 \<.001
  CRP (mg/L; normal range 0.00‐5.00)     73.20 (31.50‐128.00)     3.11 (3.11‐12.45)        \<.001
  Increased                              16 (94.1)                19 (35.2)                \<.001

Data are median (IQR) or n (%).*P* values comparing patients in the aggravated group and in the nonaggravated group are from Chi‐square test, Fisher\'s exact test, or Mann‐Whitney *U* test.

Aggravated, patients in the aggravated group; Nonaggravated, patients in the nonaggravated group.

Abbreviations: ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; AST, aspartate aminotransferase; AT, antithrombin; CRP, C‐reactive protein; DBiL, direct bilirubin; D‐D, D‐Dimers; FDP, fibrin/fibrinogen degradation products; FIB, fibrinogen; INR, international normalized ratio; LDH, lactate dehydrogenase; PT, prothrombin time; TBiL, total bilirubin; TT, thrombin time.
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For liver function test and diagnostic enzyme indexes, the values of AST, TBiL, DBiL, LDH, and CRP of patients in the aggravated group were significantly higher than those of patients in the nonaggravated group (*P* \< .05), but no difference was observed in the ALT value between two group patients. Moreover, the percentage values of AST, LDH, and CRP above their normal ranges were, respectively, higher in the aggravated patients than those in the nonaggravated patients (*P* \< .05). The percentage values of ALT, TBiL, and DBiL above their normal ranges in the aggravated patients were, respectively, equal to those in the nonaggravated patients (*P* \> .05).

3.4. Correlation analysis of blood coagulation with liver function and diagnostic enzymes in COVID‐19 patients {#ijlh13273-sec-0014}
--------------------------------------------------------------------------------------------------------------

Correlation analysis results of coagulation function parameters with liver function parameters and diagnostic enzyme indexes in COVID‐19 patients are displayed in Table [4](#ijlh13273-tbl-0004){ref-type="table"}. FIB was positively correlated with TBiL, DBiL, LDH, and CRP. APTT merely had a positive relevance to CRP, while PT and INR were simultaneously and positively correlated with AST, TBiL, DBiL, LDH, and CRP. TT had a positive relevance to ALT and a negative relevance to CRP. FDP and D‐D were positively correlated with AST, TBiL, DBiL, LDH, and CRP, while AT owned a negative relevance to AST, LDH, and CRP. Overall, the coagulation parameters have a close connection to the indexes of liver function and inflammatory factors, which implies the coagulation of COVID‐19 patients may be influenced by liver function and inflammation.

###### 

Correlation analysis of coagulation function parameters with indexes of liver function and diagnostic enzyme in COVID‐19 patients

  Parameters   ALT (U/L)                                        AST (U/L)                                          TBiL (μmol/L)                                      DBiL (μmol/L)                                      LDH (U/L)                                             CRP (mg/L)
  ------------ ------------------------------------------------ -------------------------------------------------- -------------------------------------------------- -------------------------------------------------- ----------------------------------------------------- -----------------------------------------------------
  FIB, g/L     0.122                                            0.142                                              0.285[\*](#ijlh13273-note-0012){ref-type="fn"}     0.297[\*](#ijlh13273-note-0012){ref-type="fn"}     0.353[\*\*](#ijlh13273-note-0013){ref-type="fn"}      0.397[\*\*\*](#ijlh13273-note-0014){ref-type="fn"}
  APTT, s      −0.075                                           0.121                                              0.085                                              0.072                                              0.122                                                 0.496[\*\*\*](#ijlh13273-note-0014){ref-type="fn"}
  PT, s        0.111                                            0.255[\*](#ijlh13273-note-0012){ref-type="fn"}     0.327[\*\*](#ijlh13273-note-0013){ref-type="fn"}   0.302[\*](#ijlh13273-note-0012){ref-type="fn"}     0.462[\*\*\*](#ijlh13273-note-0014){ref-type="fn"}    0.675[\*\*\*](#ijlh13273-note-0014){ref-type="fn"}
  TT, s        0.273[\*](#ijlh13273-note-0012){ref-type="fn"}   0.161                                              −0.222                                             −0.143                                             −0.119                                                −0.445[\*\*\*](#ijlh13273-note-0014){ref-type="fn"}
  INR          0.110                                            0.254[\*](#ijlh13273-note-0012){ref-type="fn"}     0.328[\*\*](#ijlh13273-note-0013){ref-type="fn"}   0.303[\*](#ijlh13273-note-0012){ref-type="fn"}     0.461[\*\*\*](#ijlh13273-note-0014){ref-type="fn"}    0.675[\*\*\*](#ijlh13273-note-0014){ref-type="fn"}
  FDP, mg/L    0.123                                            0.351[\*\*](#ijlh13273-note-0013){ref-type="fn"}   0.277[\*](#ijlh13273-note-0012){ref-type="fn"}     0.378[\*\*](#ijlh13273-note-0013){ref-type="fn"}   0.674[\*\*\*](#ijlh13273-note-0014){ref-type="fn"}    0.635[\*\*\*](#ijlh13273-note-0014){ref-type="fn"}
  D‐D, mg/L    0.147                                            0.271[\*](#ijlh13273-note-0012){ref-type="fn"}     0.270[\*](#ijlh13273-note-0012){ref-type="fn"}     0.332[\*\*](#ijlh13273-note-0013){ref-type="fn"}   0.613[\*](#ijlh13273-note-0012){ref-type="fn"}        0.476[\*\*\*](#ijlh13273-note-0014){ref-type="fn"}
  AT, %        −0.091                                           −0.271[\*](#ijlh13273-note-0012){ref-type="fn"}    −0.194                                             −0.194                                             −0.498[\*\*\*](#ijlh13273-note-0014){ref-type="fn"}   −0.470[\*\*\*](#ijlh13273-note-0014){ref-type="fn"}

Data are *r* values. The values of *r* and *P* comparing parameters of coagulation function and indexes of liver function and diagnostic enzyme are from Spearman\'s correlation analysis.

Abbreviations: ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; AST, aspartate aminotransferase; AT, antithrombin; CRP, C‐reactive protein; DBiL, direct bilirubin; D‐D, D‐Dimers; FDP, fibrin/fibrinogen degradation products; FIB, fibrinogen; INR, international normalized ratio; LDH, lactate dehydrogenase; PT, prothrombin time; TBiL, total bilirubin; TT, thrombin time.

*P* \< .05.

*P* \< .01.

*P* \< .001.
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4. DISCUSSION {#ijlh13273-sec-0015}
=============

In this study, the coagulation function results between severe COVID‐19 patients and healthy individuals were compared. The test parameters showed that FIB values in COVID‐19 patients were significantly higher than those in controls, and that values of APTT, PT, and INR were simultaneously higher in COVID‐19 patients than those in controls. These results imply that severe patients with COVID‐19 possess coagulation dysfunction. This seemingly contradictory result can be explained by that the functions of coagulation, anticoagulation, and fibrinolysis in most of the severe cases with COVID‐19 are simultaneously and negatively affected.[^6^](#ijlh13273-bib-0006){ref-type="ref"}, [^9^](#ijlh13273-bib-0009){ref-type="ref"}, [^10^](#ijlh13273-bib-0010){ref-type="ref"} Compared with healthy controls, the dramatically elevated values of FDP and D‐D and significantly reduced values of AT in severe COVID‐19 patients also confirm this conclusion. Overall, our results also bring into correspondence with those of previous studies. Thus, we reinforce the suggestion that the coagulation of severe patients with SARS‐CoV‐2 infection is a matter of particular concern.

To make clear the relations of monitoring of coagulation on admission with clinical outcomes, the enrolled COVID‐19 patients were, respectively, divided into the aggravated group and the nonaggravated group according to whether the patients\' conditions aggravated or not after admission. The routine hemostasis tests showed that similar differences with COVID‐19 patients and healthy controls were observed in the values of all coagulation parameters except for FIB value between patients in the aggravated group and in the nonaggravated group. It is likely that COVID‐19 patients with conditions deterioration after admission possess more significant coagulation dysfunction on admission than those patients without conditions deterioration. The results give us an important idea that the coagulation function of COVID‐19 patients on admission may have a close connection with their clinical outcomes, and that early monitoring of coagulation function may be essential for establishing an accurate therapeutic strategy, especially for coagulation disorders and preventing disease progression.

The liver is responsible for the synthesis and transport of many coagulation factors and anticoagulants,[^11^](#ijlh13273-bib-0011){ref-type="ref"}, [^12^](#ijlh13273-bib-0012){ref-type="ref"} and inflammation also acts as a significant role in coagulation regulation cascade network.[^13^](#ijlh13273-bib-0013){ref-type="ref"}, [^14^](#ijlh13273-bib-0014){ref-type="ref"} CRP is a kind of acute protein which rises sharply in the plasma when the body is infected or damaged, and it is a nonspecific and momentous marker of inflammation. LDH widely exists in human organs and tissues, and it is able to reflect the inflammation and injury residing in liver. The correlation analysis results demonstrated that all of the coagulation parameters had a direct connection with CRP value, prompting inflammation existing in COVID‐19 patients probably, and primarily lead to coagulation disorders. Furthermore, the close correlation between liver function indexes, LDH, and coagulation function parameters also indicates that coagulation dysfunction may be related to liver injury of COVID‐19 patients. Therefore, we speculate that different clinical outcomes caused by coagulation function may be due to the different degree of organ damage (especially liver) and the different intensity of inflammatory response in COVID‐19 patients.[^1^](#ijlh13273-bib-0001){ref-type="ref"}, [^15^](#ijlh13273-bib-0015){ref-type="ref"}, [^16^](#ijlh13273-bib-0016){ref-type="ref"}

Unfortunately, the number of patients infected by SARS‐CoV‐2 is globally exhibiting a rapid and constant progression. Although the mortality of this emerging infectious disease seems not high, severe or critical patients still possess a high risk of developing ARDS and getting poor clinical outcomes. Most of the severe or critical patients with COVID‐19 often possess coagulation disorders, which points out that coagulation function may play an important role in disease progression. Thus, accurate diagnosis of coagulation and timely treatment of coagulopathy at the early stage of disease progression may be essential for preventing the deterioration of patients\' conditions and improving the otherwise unfavorable clinical outcomes.
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